share_log

HC Wainwright & Co. Reiterates Buy on Allogene Therapeutics, Maintains $23 Price Target

Benzinga ·  Aug 7, 2023 06:21

HC Wainwright & Co. analyst Robert Burns reiterates Allogene Therapeutics (NASDAQ:ALLO) with a Buy and maintains $23 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment